$1.75 Billion is the total value of Camber Capital Management LP's 30 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 58.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CHNG | Buy | CHANGE HEALTHCARE INC | $178,080,000 | +37.1% | 15,900,000 | +22.3% | 10.19% | +31.4% |
| MYL | Buy | MYLAN N V | $176,880,000 | +52.2% | 11,000,000 | +41.1% | 10.12% | +45.8% |
| ALXN | Sell | ALEXION PHARMACEUTICALS INC | $157,136,000 | +6.1% | 1,400,000 | -15.2% | 8.99% | +1.6% |
| ALKS | Buy | ALKERMES PLC | $140,686,000 | +61.3% | 7,250,000 | +19.8% | 8.05% | +54.5% |
| PRGO | Buy | PERRIGO CO PLC | $124,358,000 | +29.3% | 2,250,000 | +12.5% | 7.12% | +23.9% |
| GSK | GLAXOSMITHKLINE PLCsponsored adr | $122,370,000 | +7.7% | 3,000,000 | 0.0% | 7.00% | +3.1% | |
| UHS | Sell | UNIVERSAL HLTH SVCS INCcl b | $92,890,000 | -16.7% | 1,000,000 | -11.1% | 5.32% | -20.1% |
| BLUE | New | BLUEBIRD BIO INC | $77,826,000 | – | 1,275,000 | +100.0% | 4.45% | – |
| NKTR | NEKTAR THERAPEUTICS | $69,480,000 | +29.7% | 3,000,000 | 0.0% | 3.98% | +24.3% | |
| IRWD | New | IRONWOOD PHARMACEUTICALS INC | $67,080,000 | – | 6,500,000 | +100.0% | 3.84% | – |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $64,136,000 | -9.6% | 400,000 | -44.8% | 3.67% | -13.4% |
| ASND | Sell | ASCENDIS PHARMA A Ssponsored adr | $51,765,000 | -14.4% | 350,000 | -34.8% | 2.96% | -17.9% |
| MYGN | Buy | MYRIAD GENETICS INC | $45,360,000 | +34.9% | 4,000,000 | +70.2% | 2.60% | +29.2% |
| BKD | Sell | BROOKDALE SR LIVING INC | $44,250,000 | -16.6% | 15,000,000 | -11.8% | 2.53% | -20.1% |
| CHRS | New | COHERUS BIOSCIENCES INC | $39,292,000 | – | 2,200,000 | +100.0% | 2.25% | – |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $35,000,000 | +7.2% | 2,000,000 | 0.0% | 2.00% | +2.7% | |
| AMAG | AMAG PHARMACEUTICALS INC | $33,584,000 | +23.8% | 4,390,000 | 0.0% | 1.92% | +18.6% | |
| GKOS | New | GLAUKOS CORP | $28,047,000 | – | 730,000 | +100.0% | 1.60% | – |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $25,032,000 | +52.1% | 2,400,000 | +23.1% | 1.43% | +45.7% |
| TEVA | New | TEVA PHARMACEUTICAL INDS LTDsponsored ads | $24,660,000 | – | 2,000,000 | +100.0% | 1.41% | – |
| AVRO | AVROBIO INC | $23,558,000 | +12.1% | 1,350,000 | 0.0% | 1.35% | +7.5% | |
| SAGE | New | SAGE THERAPEUTICS INC | $21,830,000 | – | 525,000 | +100.0% | 1.25% | – |
| ATRA | Sell | ATARA BIOTHERAPEUTICS INC | $20,398,000 | +62.1% | 1,400,000 | -5.3% | 1.17% | +55.4% |
| IMVT | New | IMMUNOVANT INC | $19,480,000 | – | 800,000 | +100.0% | 1.12% | – |
| TBIO | Sell | TRANSLATE BIO INC | $17,920,000 | +1.8% | 1,000,000 | -43.3% | 1.02% | -2.5% |
| MNTA | Sell | MOMENTA PHARMACEUTICALS INC | $14,972,000 | -72.5% | 450,000 | -77.5% | 0.86% | -73.6% |
| GLYC | Sell | GLYCOMIMETICS INC | $11,280,000 | +41.4% | 3,000,000 | -14.3% | 0.64% | +35.2% |
| New | PACIFIC BIOSCIENCES CALIF IN | $10,730,000 | – | 3,110,000 | +100.0% | 0.61% | – | |
| RDUS | New | RADIUS HEALTH INC | $5,111,000 | – | 375,000 | +100.0% | 0.29% | – |
| STRO | SUTRO BIOPHARMA INC | $4,656,000 | -23.9% | 600,000 | 0.0% | 0.27% | -27.1% | |
| NUVA | Exit | NUVASIVE INC | $0 | – | -33,630 | -100.0% | -0.10% | – |
| PACB | Exit | PACIFIC BIOSCIENCES CALIF IN | $0 | – | -2,500,000 | -100.0% | -0.46% | – |
| INCY | Exit | INCYTE CORP | $0 | – | -360,457 | -100.0% | -1.58% | – |
| THC | Exit | TENET HEALTHCARE CORP | $0 | – | -3,500,000 | -100.0% | -3.01% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -200,000 | -100.0% | -3.78% | – |
| HCA | Exit | HCA HEALTHCARE INC | $0 | – | -850,000 | -100.0% | -4.56% | – |
| VTR | Exit | VENTAS INC | $0 | – | -3,250,000 | -100.0% | -5.20% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -1,200,000 | -100.0% | -5.46% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.